{"nctId":"NCT02634346","briefTitle":"A Study of ALKS 3831 in Adults With Acute Exacerbation of Schizophrenia (the ENLIGHTEN-1 Study)","startDateStruct":{"date":"2015-12","type":"ACTUAL"},"conditions":["Schizophrenia"],"count":403,"armGroups":[{"label":"ALKS 3831","type":"EXPERIMENTAL","interventionNames":["Drug: ALK3831"]},{"label":"Olanzapine","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Olanzapine"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"ALK3831","otherNames":[]},{"name":"Olanzapine","otherNames":[]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Has a body mass index (BMI) of 18.0 - 40.0 kg/m\\^2\n* Meets criteria for the diagnosis of schizophrenia\n* Resides in a stable living situation when not hospitalized\n* Is willing and able to provide government-issued identification\n* Additional criteria may apply\n\nExclusion Criteria:\n\n* Has had a psychiatric hospitalization for more than 30 days during the 90 days before screening\n* Subject initiated first antipsychotic treatment within the past 12 months, or \\<1 year has elapsed since the initial onset of active-phase of schizophrenia symptoms\n* Subject poses a current suicide risk\n* Subject has a history of treatment resistance\n* Subject has a history of poor or inadequate response to treatment with olanzapine\n* Subject requires or has had electroconvulsive therapy (ECT) treatment in the 2-month period prior to screening\n* Subject has a diagnosis of moderate or severe alcohol or drug use disorder\n* Subject has a positive urine drug screen for opioids, amphetamine/methamphetamine, phencyclidine, or cocaine at screening\n* Additional criteria may apply","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"70 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score at Week 4","description":"This scale consists of symptom constructs (7 positive, 7 negative, 16 general psychopathology), each to be rated on a 7-point Likert-type scale of severity with 1 being absent to 7 being extreme. Minimum scores (best outcome) equals 30 (total scale); maximum scores (worst outcome) equals 210 (total scale). Change is calculated between the baseline visit and Week 4.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-23.9","spread":"1.28"},{"groupId":"OG001","value":"-22.8","spread":"1.29"},{"groupId":"OG002","value":"-17.5","spread":"1.32"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Clinical Global Impressions-Severity (CGIS) Score at Week 4","description":"The CGI-S is a 7-point scale that requires the clinician to assess how mentally ill the patient is in a specific point in time. Results indicate participants evaluated at one of the following categories: \"1: normal, not at all ill\"; \"2: borderline mentally ill\"; \"3: mildly ill\"; \"4: moderately ill\"; \"5: markedly ill\"; \"6: severely ill\"; and \"7: among the most extremely ill patients\". Results indicate a change in CGI-S score from baseline to Week 4 based on the observed data. Change is calculated between the baseline visit and Week 4.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.21","spread":"0.082"},{"groupId":"OG001","value":"-1.27","spread":"0.083"},{"groupId":"OG002","value":"-0.84","spread":"0.085"}]}]}]},{"type":"SECONDARY","title":"Incidence of Adverse Events","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"73","spread":null},{"groupId":"OG001","value":"73","spread":null},{"groupId":"OG002","value":"60","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1,"n":134},"commonTop":["Weight increased","Somnolence","Anxiety","Headache","Dry mouth"]}}}